radiopharmacological
excellent
quadruplicate
intravenously
probes25
permission
generously
shiba
ibaraki
might
unles
plos
representative
way
aqueou
TLC
may
prognosis7
315
declare
germany
nacalai
portion
10369
lett
student
your
CCK
paulsson
impact
protein
normal
copyright
carrier
pancreatic
increase
instead
family
cal
pathway
mice
five
sorafenib
radionuclide12
diagnostic
treatment
3957
spleen
aspartic
79br
tesque
undesired
dose
fukui
positron
adaptation
gene
essaghir
PET
radiosynthesi
org
generated
CA
rat
normally
124I
month
146
loc
kiyonoe
exposure
497
intended
makinoe
crossover
under
celluler
approximately
astatine
final
aid
element
kuchar
iodobenzoyl
type
interested
maziere
preclinical
bind
mbq
multi
TFA
RD
quantified
16KT0192
form
2192
keio
602
intraperitoneally
developed
CO2
modification24
rapid
amount
lindborg
determined
102
saline
regard
dif
silica
ltd
nonradioactive
145
kogawa
cancer1
524
reference
paul
dimeric
labelled
cultured
limited
radioiodinated
peter
127
targeting
RPMI
than
142
modification
affinity
some
give
204
105
left
exhibited
WST
competitive
disappeared
radioactive
knies
injecting
gleevec
biomarker
seen
oven
inhibited
methyl
cdcl3
more
BB
after
scientificreport
transforming
about
four
administraion
degasser
nahco3
agreed
spectra
organ
yamadad
adenosine
affin
engineered
1991
darmstadt
copy
seeded
structural
kumamoto
party
but
emission
anol
had
useful
iii
main
283
radioisotope
isotope
activate
1134
examined
www
life
bioorg
view
wherea
strand
AP
request
aimed
radiolabeled
accepted
DART
700
reported
production
odania
frequently
4459
counting
183
considered
discussed
yoji
ele
365
link
application
5553
autocrine
estimated
125I
corresponding
cu277se
replacing
mail
takaradad
retained
pharma
20A
brain
gassing
flow
absorbance
clin
slight
three
small
corre
yield
peprotech
similar
desirable
129
replacement
indicated
factor
takeshi
shown
scott
biodistribution
mukhopadhyay
quinolin
monoclonal
significantly
university
further
116
food
lundqvist
picture
clearly
basic
expression
analog
recovery
schultz
shaken
calculated
method
count
einarsson
glioblastoma
significant
value
ogawa
column
alpha
it
maennedorf
experimentation
PDGFRα
mice30
ment
substitution
dition
novel
ARC
charged
graphpad
radiopharmaceutical
thyroid
LRMS
vascular
1640
chemical
original
med
KIT
radiochemical
stomach
hamamatsu
TEA
processe
physi
PDGF
evaluated
file
addition
associated
indicate
DGU
DMEM
world
resonance
radiofluorine
phone
bromobenzoyl
8001
provide
demoulin
using
detector
control
200
NMR
radiogallium
703
1000
prominently
tracer
decay
869
11C
briefly
role
initial
DIPEA
2015
xxxx
HP
peracetic
energy
1537
suggest
ative
USA
eclipse
fluorinated
1986
open
401
PCT1
publisher'
purity
combined
poot
cyclotron
197
effect
approache
minute
pancrea
usable
carlsson
doe
2010
software
sunitinib
phenylalanine
either
con
regulation
switzerland
significance
deiodination
filtered
medium
300
size
plate
mobile
follow
then
hepatobiliary
triphosphate
1143
sjoblom
acetic
potentially
NJ
askoxylaki
overexpressed
without
atmosphere
selectivity
rocky
oncol
mhz
advantageou
previou
pooled
S1
ID
binding
clinical
1038
property
appropriate
excretion
139
kit
grant
sealed
133
analyzed
diisopropylethylamine
camorani
non
generally
care
radiation
containing
153
merck
anhydrou
tomography
LC
source
system
3964
instrum
dixit
therapy
fece
lead
our
2217
radiotracer
beta
meaningful
article
potential
week
probes24
implication
radiolabeling
difference
bxpc3
permitted
not
iment
expressing
derived
concentrated
modification30
example
min
ionization
added
halogen
hoc
male
2002
accu
bioactive
absorbed
fluorine
unpaired
akira
TR
797
november
probe
physical
intracellular
over
1132
bicinchoninic
differece
EJNMMI
committee
MG
kenji
400
sbrb
supported
nated
blood
ethanol
amin
model
puri
idue
334
functional
JMS
visit
inhibition
bromodestannylation
161
continue
234
REPORTS
inten
mulated
solution
position
stimulation
tine
incorporated
unbound
overall
radio
150
100
protocol
reproduction
862
yasushi
lation
2009
20AD
water
especially
evaluate
attribution
com
schlessinger
also
epidermal
alamo
rubin
infinite
pale
compounds13
part
solid
found
pure
superior
would
differentiation
http
OS
tokyo
free
gano
noninvasive
removal
evaluation
email
most
purification
before
5576
pericyte
newly
tukey
SPD
according
number
164
pharm
discussion
single
FBS
date
2855
benzo
asashima
obtained
subtype
vacuo
partition
human
available12
chloramine
enough
111in
daisuke
mas
use
made
developing
experimental
1012
163766
001
rad
anticancer
affect
exces
pietra
iodine
although
radioiodine17
000
counted
molecular
viability
order
driven
laboratory
coated
extracted
ana
statistically
mev
octanol
polypeptide
sci
designed
vitro
250
image
upregulation
pharmacokinetic
TN
condition
puritie
international
included
synthese
acetonitrile
radiohalogen
indirect
represent
imatinib
medicine
beam
robson
trifluoroacetic
disadvantage
refer
JEOL
improve
6112
emi
acces
decreased
consumed
MO
mentioned
sio2
positive
radiobromine
strict
double
CEA
permit
sport
13C
heldin
murine
pathway4
140
corrected
ann
gram
content
isoform
overnight
important
signaling
still
anti
DS
completely
contrastingly
assay
previously24
PBS
dark
xenograft
mice18
recombinant
OPEN
microplate
temperature
coefficient
68ga
mishiro
effendi
manuscript
any
tributyltin
ATP
tween
ha
technology
compare
display
chelator13
industry
case
5C18
brominated
isolation
light
bromine
amine
NBS
piperidin
centrated
another
294
20A5R
RTK
2007
aldrich
106
ice
measuring
greater
cell
based
will
accumulate
bromo
radiat
education
platelet
radiobrominated
subcutaneously
hanaoka
101
neoplasia
list
kidney
each
widely
ferent
activity
conducted
103
licensed
HPLC
proliferation
152
2004
molar
glycerophosphate
much
2188
succinimidyl
1997
labeling
verified
visualized
JCRB
summarized
mitted
STI
rev
map
clearance
profile
diluted
kil
measurement
change
PB
SHIMADZU
HMBC
when
odani
larger
several
hill
kazuhiro
solubility
effective
UV
875
proton
cancer
RXF393
onuclide
1540
compared
407
domain
old
DCM
eur
pbrv
TECAN
incorpo
approved
choice
lemmon
receptor
centration
highly
intensity
washing
emitting
purchased
phy
pdgfrs5
studie
VEGFR2
auto
221
incorporating
prognostic
lung
structures9
industrie
similarity
nakashima
capala
contrasting
370
term
intravenou
schedule
2003
into
osaka
concentration
273
probes12
drug
third
kinase
described
bromide
almost
time32
163
negative9
stromal
they
distinct
169
144
reaction
nine
ligand
radionuclide
meth
holder
cellular
range
day
ministry
SD
accumu
slightly
mishiroc
guideline
good
reduce
77se
dasatinib21
cpm
pathol
RDS
rated
acid
research
lower
iodinated
identity
siemen
141
one
compound
endothelial
there
activated
live
therapeutic
presented
jurisdictional
phase
recently
used
allow
mean
wrote
kitamuraf
tin
341
018
sodium
4460
114
bank
211
phosphorylation
patient
sacrificed
should
show
ABL1
magnetic
confirmed
same
directly
hydrogen
156
trigger
large
tolmachev
18F
information
cre
propertie
available
standard
displacing
PDGFRβ
aptamer
SCIENTIFIC
mixture
tran
chromatogram
intestine
supplementary
decomposition
fluorine12
oliveira
bearing
hydrogensulfite
steric
113
496
int
gamma
june
high
chung
kbq
namely
biological
removing
itie
japan
distribution
derivative
blocking
reversed
identified
bhattacharyya
minimize
molecule
inc
knoxville
imaging
need
their
ogawaa
competing
shoulder
cosmosil
MS
yellow
negligible
strategy
ling
labe
affibodie
allowed
benezra
art
BCA
appl
bro
produced
ion
DMSO
afford
inhibitory
statisticaly
expressed
influence
post
isotope11
biol
S2
TKI
MCF7
material
determination
RP
benzimidazole
additionally
published
NCS
synthesized
quenched
81br
radioiodine
sharing
gallium
ranging
channel
therapy6
mulate
radi
kev
retention
targeted
kyoto
pdgfrbeta
dissolved
preparation
lo
isotopically
develop
adjusted
791
antibiotic
respectively
variou
displayed
promising
SLC
previously
solvent
buffer
radioiodi
fraction
metal
115
solu
respond
ratio
meanwhile
female
uncontrollable
cold
498
COSY
radioactivity
600
followed
commercialy
lyzed
ANOVA
cytokine
only
alter
loevqvist
thu
77br
0HPLC
product
oncology
longer
institutional
450
II
incubated
amino
imidazol
ESI
creative
luc
layer
molecules12
oxidative
enriched
155
shaking
paper
science
ddy
structure
because
1981
long
incubation
springer
sep
otherwise
needed
counter
modestannylation
118
regulate
methoxyethoxy
buffered
contributed
doi
prediction
ahlstroem
twice
giovannetti
agent
HMQC
table
exceed
log
rodent
212
per
preparing
analysi
sundin
line
consistent
decayed
nature
animal
T100TD
could
radiosensitization
test
real
Z09591
error
demonstrated
28529
metabolism
postinjection
showed
2850
development
tail
optimized
other
accompanie
eluent
site
110
index
migration
boromine
labeled
mixed
treated
neutral
fication
nucl
biomedical
tion
broekman
present
radiometal
bromination
colorles
stirred
decreasing
PDGFB
1117
experi
deviation
571
new
iodo
stocklin
precursor
calculating
659
241
analyse
828
vial
observed
best
rate
298
bromosuccinimide
15O
peptide
inoculation
direct
dependent
ECS400
reduced
2222
175
investigated
arated
washed
na2so4
wa
effendia
specific
incubator
ideal
furthermore
quinoline
439
housed
dodecapeptide
recorded
wako
injected
creativecommon
interesting
such
require
sunitinib23
administration
chlorosuccinimide
123I
nanoformulation
109
iodide
dalton
13N
vesamicol
2014
dose16
stable
extracellular
yamada
removed
2012
imatinib20
experiment
fig
injection
fax
author
vivo
via
heated
lipophilicity
metallic
121
sity
contribute
chromatography
culture
antibody
445
dried
dichloromethane
dunnett
breast
percent
tungsten
2013
isot
rel
ple
correlation
149
all
chem
F200
ther
bull
study
similer
BALB
fredriksson
different
488
abundance
tumorigenesi
statistical
network
carried
16H01332
reader
growth
half
dojindo
beta1
including
interest
angiosarcoma
shibaf
urine
relatively
uptake
survival
note
accuflex
palpable
sponding
between
however
BCR
umol
figure
saturated
nuclear
equally
inte
tyrosine
through
format
required
ostman
exper
tumor
accordance
2017
DOTA
2018
smaller
scientific
reagent
claim
s41598
suggesting
malmborg
moreover
nurmaya
acylation
pro
76br
879
re
e84335
395
introduced
synthesi
time
background
137
oxidizing
short
easily
group
chloroform
nonradiolabeled
report
loui
affibody
describe
performed
residue
heart
comparison
bound
contrast
126
sample
651
received
130
therefore
gradient
variance
well
density
443
713
mol
carbon
credit
during
obtain
license
data
angiogenesi
indicating
bone
coincubated
peak
JNM
comparable
mmol
jolla
kanto
respectively24
yonemori
target
often
work
bromobenzoate
liver
841
contain
six
hitachi
correspondence
common
naoh
conclusion
santo
derivatives11
CTO
low
2841
inorg
incorporation
resected
every
246
two
112
multiple
N2
regression
result
out
5585
prepared
phosphate
reached
radioligand
surg
accumulation
resolution
muscle
methanol
nonlinear
heating
room
eriksson
reported8
tissue
electrospray
higher
reviewed
both
RGD
pump
affiliation
sigma
PDGFR
organic
above
inhibitor
131I
um9
statutory
characteristic
weighed
kanazawa
dasatinib
optical
ence
first
remain
oligo
6128
purified
1998
2011
exam
IC50
addressed
stability
intermediate
pretreatment
kazuma